Literature DB >> 12584311

Presence of replicating virus in recombinant hepadnavirus stocks results from recombination and can be eliminated by the use of a packaging cell line.

Uta Klöcker1, Heike Oberwinkler, Timo Kürschner, Ulrike Protzer.   

Abstract

Mutant hepatitis B viruses are useful tools to study the viral life cycle and viral pathogenesis. Furthermore, recombinant hepatitis B viruses are candidate vectors for liver-directed gene therapy. Because wild-type viruses present in recombinant or mutant virus stocks may falsify experimental results and are detrimental for a viral vector, we investigated whether and to what extent wild-type virus is present in recombinant virus stocks and where it originates from. We took advantage of the duck model of hepatitis B virus infection which allows very sensitive detection of replication-competent viruses by infection of primary duck hepatocytes or of ducklings in vivo. Recombinant hepatitis B virus stocks contained significant amounts of wild-type viruses, which were most probably generated by homologous recombination between plasmids containing homologous viral sequences. In addition, replication-competent viral genomes were reconstituted from plasmids which contained replication-deficient but redundant viral sequences. Using a stable cell line for packaging of deficient viral genomes, no wild-type virus was detected, neither by infection of primary hepatocytes nor in vivo.

Entities:  

Mesh:

Year:  2003        PMID: 12584311      PMCID: PMC149740          DOI: 10.1128/jvi.77.5.2873-2881.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Nonreciprocal exchanges of information between DNA duplexes coinjected into mammalian cell nuclei.

Authors:  K R Folger; K Thomas; M R Capecchi
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

2.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

3.  Cloned HBV DNA causes hepatitis in chimpanzees.

Authors:  H Will; R Cattaneo; H G Koch; G Darai; H Schaller; H Schellekens; P M van Eerd; F Deinhardt
Journal:  Nature       Date:  1982-10-21       Impact factor: 49.962

4.  Homologous recombination between hepadnaviral genomes following in vivo DNA transfection: implications for studies of viral infectivity.

Authors:  R Sprengel; H E Varmus; D Ganem
Journal:  Virology       Date:  1987-08       Impact factor: 3.616

5.  Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.

Authors:  E Mandart; A Kay; F Galibert
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  Experimental transmission of duck hepatitis B virus.

Authors:  W S Mason; M S Halpern; J M England; G Seal; J Egan; L Coates; C Aldrich; J Summers
Journal:  Virology       Date:  1983-12       Impact factor: 3.616

7.  The cloned genome of ground squirrel hepatitis virus is infectious in the animal.

Authors:  C Seeger; D Ganem; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

8.  Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription.

Authors:  M Büscher; W Reiser; H Will; H Schaller
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

9.  Homologous and nonhomologous recombination in monkey cells.

Authors:  S Subramani; P Berg
Journal:  Mol Cell Biol       Date:  1983-06       Impact factor: 4.272

10.  Cloned duck hepatitis B virus DNA is infectious in Pekin ducks.

Authors:  R Sprengel; C Kuhn; C Manso; H Will
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

View more
  1 in total

1.  High expression of hepatitis B virus based vector with reporter gene in hepatitis B virus infection system.

Authors:  Shi-Hong Li; Wen-Ge Huang; Bing Huang; Xi-Gu Chen
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.